DLBS1033 for Acute Ischemic Stroke Patients

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 11, 2014

Primary Completion Date

February 21, 2023

Study Completion Date

April 21, 2023

Conditions
Acute Ischemic StrokePartial Anterior Circulation InfarctLacunar Anterior Circulation Infarct
Interventions
DRUG

DLBS1033

Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet

DRUG

Placebo

Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet

Trial Locations (10)

Unknown

Neurology Department, Dr. Kariadi General Hospital, Semarang

Universitas Sebelas Maret (UNS) Hospital, Sukoharjo

Dr. Moewardi Hospital, Surakarta

Neurology Department Fatmawati Regional General Hospital, Jakarta

Neurology Department, Budhi Asih Hospital, Jakarta

Neurology Department, Pasar Rebo Hospital, Jakarta

Neurology Department Islam Jakarta Hospital (RSIJ) Cempaka Putih, Jakarta Pusat

Neurology Department Sidoarjo Regional General Hospital, Sidoarjo

Neurology Department, Haji Surabaya Hospital, Surabaya

Stroke/Cerebrobascular Division, Neurology Department, Dr. Soetomo Hospital, Surabaya

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Dexa Medica Group

INDUSTRY

NCT02133521 - DLBS1033 for Acute Ischemic Stroke Patients | Biotech Hunter | Biotech Hunter